Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 28;8(3):249.
doi: 10.3390/jof8030249.

Surveillance of Antifungal Resistance in Candidemia Fails to Inform Antifungal Stewardship in European Countries

Affiliations

Surveillance of Antifungal Resistance in Candidemia Fails to Inform Antifungal Stewardship in European Countries

Liliana Galia et al. J Fungi (Basel). .

Abstract

Background: The increasing burden of candidemia and the emergence of resistance, especially among non-Candida albicans strains, represent a new threat for public health. We aimed to assess the status of surveillance and to identify publicly accessible resistance data in Candida spp. blood isolates from surveillance systems and epidemiological studies in 28 European and 4 European Free Trade Association member states.

Methods: A systematic review of national and international surveillance networks, from 2015 to 2020, and peer-reviewed epidemiological surveillance studies, from 2005 to 2020, lasting for at least 12 consecutive months and with at least two centers involved, was completed to assess reporting of resistance to amphotericin B, azoles, and echinocandins in C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, and C. auris.

Results: Only 5 (Austria, Italy, Norway, Spain, and United Kingdom) of 32 countries provided resistance data for Candida spp blood isolates. Among 322 surveillance studies identified, 19 were included from Belgium, Denmark, Iceland, Italy, Portugal, Spain, Sweden, Switzerland, and United Kingdom. C. albicans and C. glabrata were the most monitored species, followed by C. parapsilosis and C. tropicalis. C. krusei was not included in any national surveillance system; 13 studies assessed resistance. No surveillance system or study reported resistance for C. auris. Fluconazole, voriconazole, caspofungin, and amphotericin B resistance in C. albicans, C. glabrata, and C. parapsilosis were the most common drug-species combination monitored. Quality of surveillance data was poor, with only two surveillance systems reporting microbiological methods and clinical data. High heterogeneity was observed in modalities of reporting, data collection, and definitions.

Conclusion: Surveillance of antifungal resistance in Candida spp blood-isolates is fragmented and heterogeneous, delaying the application of a translational approach to the threat of antifungal resistance and the identification of proper targets for antifungal stewardship activities. International efforts are needed to implement antifungal resistance surveillance programs in order to adequately monitor antifungal resistance.

Keywords: candidemia; resistance; stewardship; surveillance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Countries with availability of surveillance data of resistance in candidemia; description of systems is provided in Supplementary Material File S3. Green: countries providing Candida spp. resistance data in bloodstream infections; yellow: countries providing Candida spp. resistance data from mixed samples (all isolates); light blue: countries provided Candida isolates stratified by infection type without resistance; red: countries not providing any data on resistance of Candida spp.

Similar articles

Cited by

References

    1. Cuervo G., Garcia-Vidal C., Puig-Asensio M., Merino P., Vena A., Martin-Pena A., Montejo J.M., Ruiz A., Lazaro-Perona F., Fortun J., et al. Usefulness of guideline recommendations for prognosis in patients with candidemia. Med. Mycol. 2019;57:659–667. doi: 10.1093/mmy/myy118. - DOI - PubMed
    1. Koehler P., Stecher M., Cornely O.A., Koehler D., Vehreschild M., Bohlius J., Wisplinghoff H., Vehreschild J.J. Morbidity and mortality of candidaemia in Europe: An epidemiologic meta-analysis. Clin. Microbiol. Infect. 2019;25:1200–1212. doi: 10.1016/j.cmi.2019.04.024. - DOI - PubMed
    1. Fournier P., Schwebel C., Maubon D., Vesin A., Lebeau B., Foroni L., Hamidfar-Roy R., Cornet M., Timsit J.F., Pelloux H. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J. Antimicrob. Chemother. 2011;66:2880–2886. doi: 10.1093/jac/dkr394. - DOI - PubMed
    1. Shah D.N., Yau R., Lasco T.M., Weston J., Salazar M., Palmer H.R., Garey K.W. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob. Agents Chemother. 2012;56:3239–3243. doi: 10.1128/AAC.00019-12. - DOI - PMC - PubMed
    1. Schwartz I.S., Patterson T.F. The Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases. Curr. Infect. Dis. Rep. 2018;20:2. doi: 10.1007/s11908-018-0608-y. - DOI - PubMed

LinkOut - more resources